Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer
โ Scribed by Hideo Inaji; Hiroji Iwata; Takahiro Nakayama; Naohito Yamamoto; Yasuyuki Sato; Yutaka Tokuda; Kenjiro Aogi; Shigehira Saji; Kenichi Watanabe; Tsuyoshi Saito; Masayuki Yoshida; Nobuaki Sato; Toshiaki Saeki; Yuichi Takatsuka; Masaru Kuranami; Hiroko Yamashita; Atsushi Kikuchi; Toshio Tabei; Tadashi Ikeda; Shinzaburo Noguchi
- Book ID
- 114703325
- Publisher
- John Wiley and Sons
- Year
- 2012
- Tongue
- English
- Weight
- 146 KB
- Volume
- 103
- Category
- Article
- ISSN
- 1347-9032
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi